All Stories

  1. Prognostic significance of pretreatment anemia in patients with advanced cutaneous melanoma
  2. Relapse after Excision of Melanoma in situ
  3. Locoregional relapse after excision of cutaneous melanoma
  4. Association of superior vena cava syndrome with small cell lung cancer
  5. Clinical significances of variations in main hematological parameters at the time of diagnosis in patients with small cell lung cancer
  6. Associations of Increasing Serum Lactate Dehydrogenase Levels With Chemotherapy Responsiveness and Survival in Patients With Extensive Disease Small Cell Lung Cancer
  7. Temozolomide After Excision of Lung Metastases in Patients With Melanoma
  8. Sex Difference Has No Effect on Survival in Pancreatic Cancer
  9. Access to current medicines in the treatment of Turkish melanoma patients
  10. Age-related Survival Declines in Turkish Patients with Cutaneous Melanoma: A Retrospective Analysis
  11. Effects of Home-Based Exercise Program on Chemotherapy-Induced Peripheral Neuropathy and Quality of Life
  12. Nivolumab-induced immune-mediated acute gastritis in a melanoma patient
  13. Effects of Age, Gender, Histopathology, and Anatomical Location of the Lesion on BRAF Mutation in Turkish Cutaneous Melanoma Patients
  14. A Melanosis Patient with Primary Unknown Metastatic Melanoma: Successful Treatment with BRAF/MEK Inhibitors
  15. CAN LYVE-1 MOLECULE BE A DIAGNOSTIC BIOMARKER IN PATIENTS WITH ADVANCED LUNG CANCER?
  16. Brain metastases during follow-up of patients with resected cutaneous melanoma
  17. Avoiding Cutaneous Melanoma Requires Proper Sun Protection and a Correspondingly High Level of Education: A Case Control Study
  18. Clinical significances of TTF-1, neuroendocrine (chromogranin, synaptophysin, CD56), and keratin (pancytokeratin, CK7, CK5/6) marker immunostaining in small cell lung cancer
  19. FEMALE PATIENTS WITH SMALL CELL LUNG CANCER HAVE BETTER SURVIVAL THAN MALES WITH EXTENSIVE BUT NOT LIMITED DISEASE
  20. Prognostic significance of body mass index and serum albumin as the indicators of nutritional status in small cell lung cancer
  21. Comorbidity in Small Cell Lung Cancer: Prognostic Impacts of Hypertension/Coronary Artery Disease, Diabetes Mellitus, and Chronic Obstructive Pulmonary Disease
  22. A Modified H-index Calculated Using the Duration of Professional Experience and the Author's Significant Contribution to Publications
  23. Timing of chemotherapy after diagnosis of small cell lung cancer
  24. Effect of Histological Subtype on Metastasis Distribution in Resected Cutaneous Melanoma
  25. Primary tumor SUVmax and ratio of SUVmax to primary tumor size on pretreatment 18F-FDG-PET/CT scan in small cell lung cancer
  26. Turkey's contribution to cancer publication: Expected quantity, unsatisfactory quality
  27. Diagnosing lung cancer at a younger age and with male dominance: Comparison of Turkish patients with United States patients
  28. Online public interest in smoking and lung cancer: A comparative study in Google Trends
  29. Melanoma publications do not increase as much as the incidence of melanoma in the last two decades
  30. Neither the presence nor the severity of hyponatremia affected the outcome of the patients with small cell lung cancer
  31. Intraabdominal splenosis due to traffic accident
  32. Ulceration vs Mitosis in Cutaneous Melanoma: which is Superior for Predicting Prognosis Across Clinical Stages?
  33. Median Age of Cutaneous Melanoma Presentation in Turkey from a Single Tertiary Center Is Younger Than Other Western Countries
  34. Breast cancer patients are diagnosed at younger ages in Turkey: a comparative study
  35. Completion Lymph Node Dissection Is Unnecessary After Positive Sentinel Lymph Node in Melanoma — a Case Series Analysis
  36. Major Histotypes in Skin Melanoma: Nodular and Acral Lentiginous Melanomas Are Poor Prognostic Factors for Relapse and Survival
  37. Using Google as a Source of Information About Breast Cancer
  38. Trunk melanomas: no survival differences between lesion sites
  39. Successful Treatment of a 92-Year-Old Classic Kaposi's Sarcoma Man With Ultra-Low Dose Oral Etoposide
  40. Seasons Influence Diagnosis of Breast Cancer in Turkey
  41. Cutaneous melanoma survival rates of the elderly are not worse than those of the young, yet they have some specific differences
  42. Different mitotic rates are associated with different prognostic factors, relapses, and survival rates in melanoma
  43. Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma: retrospective real‐life data
  44. Digit melanomas are associated with poor prognostic factors and unfavorable survivals
  45. Larger Tumors Are Associated with Poorer Prognostic Factors in Cutaneous Melanoma
  46. Unknown Primary Metastatic Melanoma Presented with Extensive Subcutaneous Masses and Lymph Node Enlargements
  47. Auricular and periauricular melanomas have similar clinicopathologic factors and survival rates
  48. Mitotic rate in node-positive stage III melanoma: it might be as important a prognostic factor as node number
  49. Coexistence of regression and tumor infiltrating lymphocytes is associated with more favorable survival in melanoma
  50. Serum folate and vitamin B12 levels in cutaneous melanoma
  51. Limb melanomas: acral melanomas have worse survival
  52. Complementary and alternative medicine (CAM) in Turkish cutaneous melanoma patients: A prospective study from tertiary cancer center
  53. Primary tumour ulceration in cutaneous melanoma: its role on TNM stages.
  54. Awareness on malignant melanoma and its prevention measures among Turkish cutaneous malignant melanoma patients: A tertiary cancer center experience
  55. Google searching as an indicator of population's interest in melanoma: A comparative study in Google Trends
  56. Multiple combinations of melanocytic and vascular endothelial markers enhances the detection rate of lymphovascular invasion in cutaneous melanoma
  57. Serum 25-Hydroxyvitamin D Level Is Not Associated with Duration and Activity of Disease in Melanoma Patients
  58. Paradox in melanoma
  59. De Novo and Nevus-Associated Melanomas: Different Histopathologic Characteristics but Similar Survival Rates
  60. SEASONS INFLUENCE DIAGNOSIS AND OUTCOME OF CUTANEOUS MELANOMA
  61. Single-agent temozolomide may be an effective option for late adjuvant therapy in patients with melanoma
  62. BRAF V600E mutation as a prognostic factor in cutaneous melanoma patients
  63. Cutaneous melanoma in vicenarians: Patients in their twenties and older patients show similar clinical behaviors and survival rates
  64. Trends in the characteristics of skin melanoma in accordance with time intervals: A single Turkish tertiary referral center experience
  65. Distichiasis in association with entropion in metastatic HER2‐positive breast cancer treated by pertuzumab, trastuzumab, and docetaxel combination chemotherapy
  66. Number of Excised Lymph Nodes Has No Impact on Relapse and Survival in Patients With Stage III Melanoma
  67. Serum nectin-2 and nectin-4 are diagnostic in lung cancer: which is superior?
  68. The course of stage III melanoma in accordance with the severity of node involvement
  69. Spitzoid cutaneous melanoma is associated with favorable clinicopathological factors and outcome
  70. BRAF mutation status might contribute an effect on both disease-free and overall survival in stage III cutaneous melanomas treated with intermediate dose interferon-alpha
  71. Cheek Cutaneous Melanomas
  72. Lymph node ratio has impact on relapse and outcome in patients with stage III melanoma
  73. Early and late relapses of cutaneous melanoma patients
  74. Clinical and prognostic significance of BRAF V600E mutation in non-metastatic cutaneous melanoma patients
  75. Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer
  76. Significant Neutrophilic Emperipolesis in Squamous Cell Carcinoma
  77. Relapse patterns in patients with local and regional cutaneous melanoma
  78. Palpebral cutaneous melanomas: a review of 17 cases from a tertiary center
  79. Clinical significance of serum leptin level in patients with gastric cancer
  80. Widespread finger skin metastases of melanoma
  81. Acral Lentiginous Melanoma Is Associated with Certain Poor Prognostic Histopathological Factors but May Not be Correlated with Nodal Involvement, Recurrence, and a Worse Survival
  82. Neurotropism as a prognostic factor in cutaneous melanoma patients
  83. Anemia in Cutaneous Malignant Melanoma: Low Blood Hemoglobin Level is Associated with Nodal Involvement, Metastatic Disease, and Worse Survival
  84. Digital clubbing as a first clinical presentation of pulmonary metastases in cutaneous melanoma
  85. Significance of serum neural precursor cell‑expressed developmentally downregulated protein 9 in melanoma
  86. Cutaneous Melanoma in Association With Ichthyosis Vulgaris
  87. Effect of biology on the outcome of female melanoma patients
  88. Elevated erythrocyte sedimentation rate is associated with metastatic disease and worse survival in patients with cutaneous malignant melanoma
  89. Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival
  90. Plantar melanoma is associated with certain poor prognostic histopathological factors, but not correlated with nodal involvement, recurrence, and worse survival
  91. Tumor Infiltrating Lymphocytes (TILs) May be Only an Independent Predictor of Nodal Involvement but not for Recurrence and Survival in Cutaneous Melanoma Patients
  92. Scalp melanoma is associated with high mitotic rate and is a poor prognostic factor for recurrence and outcome
  93. Recurrence behavior in early-stage cutaneous melanoma
  94. Circulating interleukin-18 (IL-18) is a predictor of response to gemcitabine based chemotherapy in patients with pancreatic adenocarcinoma
  95. Histological lymphovascular invasion is associated with nodal involvement, recurrence, and survival in patients with cutaneous malignant melanoma
  96. Presence of histological regression as a prognostic factor in cutaneous melanoma patients
  97. Clinical significance of serum claudin-1 levels in melanoma patients
  98. Clinical significance of serum Protease-Activated Receptor-1 (PAR-1) levels in patients with cutaneous melanoma
  99. Clinical Significance of Serum Galectin-3 Levels in Gastric Cancer Patients
  100. Is it solitary plasmacytoma or nonsecretory myeloma? A must-be-solved dilemma?
  101. Same Chemotherapy Regimen Leads to Different Myelotoxicity in Different Malignancies
  102. Zosteriform type in-transit metastasis of melanoma
  103. Majority of the most-cited articles on cutaneous malignant melanoma are published in non-dermatology/melanoma specialized journals
  104. Clinical significance of serum caveolin-1 levels in melanoma patients
  105. D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients
  106. Exacerbation of psoriasis induced by interferon-alpha treatment for melanoma
  107. Clinical significance of serum interleukin-18 (IL-18) levels in patients with gastric cancer
  108. Circulating annexin A2 as a biomarker in gastric cancer patients: Correlation with clinical variables
  109. tas f
  110. Clinical significance of serum epidermal growth factor receptor (EGFR) levels in patients with breast cancer
  111. Combination of Capecitabine and Phenytoin May Cause Phenytoin Intoxication
  112. Serum transforming growth factor-beta1 levels may have predictive and prognostic roles in patients with gastric cancer
  113. Clinical significance of serum M30 and M65 levels in patients with breast cancer
  114. Clinical significance of serum fibronectin and vitronectin levels in melanoma patients
  115. Clinical significance of serum epithelial cell adhesion molecule (EPCAM) levels in patients with lung cancer
  116. Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein-3 (IGFBP-3) in patients with breast cancer
  117. Serum levels of vascular cell adhesion molecule-1 (VCAM-1) may have diagnostic, predictive, and prognostic roles in patients with lung cancer treated with platinum-based chemotherapy
  118. Serum transforming growth factor-beta 1 (TGF-β1) levels have diagnostic, predictive, and possible prognostic roles in patients with melanoma
  119. High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer
  120. Clinical significance of serum tenascin-c levels in epithelial ovarian cancer
  121. Serum levels of LDH, CEA, and CA19-9 have prognostic roles on survival in patients with metastatic pancreatic cancer receiving gemcitabine-based chemotherapy
  122. Coagulation tests show significant differences in patients with breast cancer
  123. Clinical significance of serum ADP-ribosylation and NAD glycohydrolase activity in patients with colorectal cancer
  124. Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer
  125. An analysis of the most-cited research papers on oncology: which journals have they been published in?
  126. Clinical significance of serum transforming growth factor-beta 1 (TGF-β1) levels in patients with epithelial ovarian cancer
  127. Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in patients with epithelial ovarian cancer
  128. Serum levels of macrophage migration-inhibitory factor (MIF) have diagnostic, predictive and prognostic roles in epithelial ovarian cancer patients
  129. Clinical significance of serum insulin-like growth factor-1 (IGF-1) and insulinlike growth factor binding protein-3 (IGFBP-3) in patients with epithelial ovarian cancer
  130. Clinical significance of serum M30 and M65 levels in melanoma
  131. Age is a prognostic factor affecting survival in lung cancer patients
  132. A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer
  133. Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma
  134. Clinical Significance of Coagulation Assays in Metastatic Pancreatic Adenocarcinoma
  135. Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survival
  136. Clinical and Prognostic Significance of Coagulation Assays in Gastric Cancer
  137. Clinical and prognostic significance of coagulation assays in lung cancer
  138. Triplet chemotherapy combination with cisplatin, gemcitabine and docetaxel in patients with chemotherapy‑naive advanced non-small cell lung cancer
  139. Recurrent Gastric Cancer Presenting with Both Scrotal and Facial Skin Metastases: A Case Report
  140. Clinical and Prognostic Significance of Coagulation Assays in Advanced Epithelial Ovarian Cancer
  141. Adrenocortical Carcinoma: Clinicopathological Features, Prognostic Factors and Outcome
  142. Mucosal Melanoma in the Head and Neck Region: Different Clinical Features and Same Outcome to Cutaneous Melanoma
  143. Clinical and prognostic significance of coagulation assays in melanoma
  144. Performance status of patients is the major prognostic factor at all stages of pancreatic cancer
  145. Age-specific incidence ratios of lung cancer (LC) in Turkey: LC in older people is increasing
  146. Age-specific incidence ratios of colorectal cancer (CRC) in Turkey: CRC in older people is increasing
  147. Age-specific incidence ratios of breast cancer (BC) in Turkey: BC in older people is increasing
  148. The roles of surgery and EMA/CO chemotherapy regimen in primary refractory and non-refractory gestational trophoblastic neoplasia
  149. Factors Influencing the Hormone Receptor and HER2 Levels in Breast Cancer: A Population-Based Analysis
  150. Metastatic Behavior in Melanoma: Timing, Pattern, Survival, and Influencing Factors
  151. Classic Kaposi′s sarcoma with colonic involvement: A rare presentation with successful treatment with oral etoposide
  152. Association of clinical and pathological variables with survival in thymoma
  153. Melanoma-assocıated hypopıgmentatıon ın assocıatıon wıth locoregıonal relapse of melanoma
  154. Induction Chemotherapy With Triweekly Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy With or Without Surgery in Stage III Non–Small-Cell Lung Cancer: A Phase II Study
  155. The major stressful life events and cancer: stress history and cancer
  156. Noncutaneous Melanoma Have Distinct Features from Each Other and Cutaneous Melanoma
  157. Cardiac involvement in melanoma: A case report and review of the literature
  158. Statistical Interpretation of CA125 and Bcl-2 in Serum of Patients With Late Stage Ovarian Cancer
  159. Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer
  160. A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer
  161. Circulating levels of vascular endothelial growth factor (VEGF), matrix metalloproteinase-3 (MMP-3), and BCL-2 in malignant melanoma
  162. The Role of Serum Vascular Endothelial Growth Factor and Matrix Metalloproteinase-9 in Predicting Response to Chemotherapy in Patients with Advanced Nonsmall Cell Lung Cancer
  163. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer
  164. Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases
  165. Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer
  166. Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer
  167. Serum levels of intercellular adhesion molecule ICAM-1 and E-selectin in advanced stage non-small cell lung cancer
  168. Temozolomide in combination with fotemustine in patients with metastatic melanoma
  169. Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma
  170. Effect of maximum-tolerated doses and low-dose metronomic chemotherapy on serum vascular endothelial growth factor and thrombospondin-1 levels in patients with advanced nonsmall cell lung cancer
  171. Serum IL-8 and IL-12 levels in breast cancer
  172. The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer
  173. Pattern and Outcome of admission to a medical oncology inpatient service
  174. Macrophage Migration Inhibitory Factor in Cancer
  175. Sentinel lymph node biopsy for the staging of anal melanoma: Report of two cases
  176. Increased sister chromatid exchange frequency in young women with breast cancer and in their first-degree relatives
  177. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients
  178. Penile metastasis of cutaneous malignant melanoma: a true hematogenous spread?
  179. Serum Vascular Endothelial Growth Factor (VEGF) and Interleukin-8 (IL-8) Levels in Small Cell Lung Cancer
  180. The Value of Serum bcl-2 Levels in Advanced Epithelial Ovarian Cancer
  181. Intermediate Dose Interferon Alpha in Adjuvant Treatment for High-Risk Melanoma: A Single Institution's Experience
  182. Serum Vascular Endothelial Growth Factor (VEGF) and Bcl-2 Levels in Advanced Stage Non-Small Cell Lung Cancer
  183. Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial
  184. The prevalence and determinants of the use of complementary and alternative medicine in adult Turkish cancer patients
  185. Oxidative Stress in Breast Cancer
  186. Serum Levels of Leptin and Proinflammatory Cytokines in Advanced-Stage Non-Small Cell Lung Cancer
  187. Serum Matrix Metalloproteinase-3 and Tissue Inhibitor of Metalloproteinase-1 in Patients with Malignant Melanoma
  188. The Value of Serum Bcl-2 Levels in Advanced Lung Cancer Patients
  189. Apoptosis of Lymphocytes in Peripheral Blood of Patients with Melanoma
  190. The Value of Serum Levels of IL-6, TNF-alpha, and Erythropoietin in Metastatic Malignant Melanoma: Serum IL-6 Level Is a Valuable Prognostic Factor at Least as Serum LDH in Advanced Melanoma
  191. Serum bcl-2 and survivin levels in melanoma
  192. Clinical Value of Protein S100 and Melanoma-Inhibitory Activity (MIA) in Malignant Melanoma
  193. MASSIVE AND ISOLATED METASTASES TO SPLEEN OF UVEAL MALIGNANT MELANOMA
  194. Second-Line Docetaxel and Gemcitabine Combination Chemotherapy in Patients with Non-Small-Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy: A Phase II Trial
  195. Granulosa Cell Tumor of the Ovary
  196. Retrovesical Soft-Tissue Metastasis of Malignant Thymoma
  197. Correspondence
  198. Adjuvant Intraperitoneal Chemotherapy With Cisplatinum, Mitoxantrone, 5-Fluorouracil, and Calcium Folinate in Patients With Gastric Cancer
  199. Anemia in Oncology Practice
  200. Safety of Paclitaxel in a Patient with Ovarian Cancer and Hyperbilirubinemia Due to Rotor's Syndrome
  201. Prognostic Role of nm23 Gene Expression in Patients With Ovarian Cancer
  202. Prognostic Factors in Pancreatic Carcinoma
  203. Treatment of Aggressive Non-Hodgkin’s Lymphoma With Dose-Intensified Epirubicin in Combination of Cyclophosphamide, Vincristine, and Prednisone (CEOP-100)
  204. Stevens-Johnson Syndrome in a Patient Receiving Anticonvulsant Therapy During Cranial Irradiation
  205. Serum Lactate Dehydrogenase Levels at Presentation Predict Outcome of Patients With Limited-Stage Small-Cell Lung Cancer
  206. Measurement of Serum CA 19-9 May Be More Valuable Than CEA in Prediction of Recurrence in Patients With Gastric Cancer
  207. Angiogenesis and p53 Protein Expression in Breast Cancer
  208. Multiple Primary Neoplasms at a Single Institution
  209. Celsite® port and catheter as an intraperitoneal access device in the treatment of ovarian cancer
  210. Serum levels of the soluble adhesion molecules in patients with malignant melanoma
  211. The Roles of Chemotherapy and Surgery in Gastric Carcinoma and the Influence of Prognostic Factors on Survival
  212. Celsite� port and catheter as an intraperitoneal access device in the treatment of ovarian cancer
  213. Factors Influencing the Distribution of Metastases and Survival in Extensive Disease Small Cell Lung Cancer
  214. A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5‐fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma